


# TOP ABSTRACTS

## International Congress of Parkinson's Disease and Movement Disorders®



August 27-31, 2023  
Copenhagen  
**DENMARK**



International Parkinson and  
Movement Disorder Society

# 2023 International Congress Top Abstracts

---

## Session 2403

Monday, August 29, 15:00 – 17:00  
Location: Auditorium 12 (First floor)

799

Oh man: Why are males more prone to Musician's Dystonia?

## Session 2404

Monday, August 29, 15:00 - 17:00

998

Botulinum toxin-A in head and upper extremities tremor. A hand-made option

1429

Response to Levodopa in Parkinson's Disease Over Time. A 4-year Follow-up Study.

## Session 2405

Monday, August 29, 15:00 – 17:00

106

A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson's disease dementia.

## Session 3408

Tuesday, August 30, 15:00 – 17:00  
Location: Auditorium 12 (First floor)

681

Clinical spectrum, imaging characteristics and care giver burden assessment of early onset non-dominant progressive cerebellar ataxias

1176

Can very early levodopa prevent self-injury in Lesch-Nyhan Disease?

## Session 3409

Tuesday, August 30, 15:00 – 17:00  
Location: Auditorium 15 (First floor)

1002

Essential tremor and essential tremor plus are essentially similar on electrophysiological tremor analysis

1656

Improved Tremor Response to Focused Ultrasound Thalamotomy

## Session 3410

Tuesday, August 30, 15:00 – 17:00  
Location: C1-M2 (Ground floor)

1265

Alzheimer's Disease Co-pathology and its Influence on Biofluid Biomarkers in Autopsied Subjects from the PPMI Study

## Session 3411

Tuesday, August 30, 15:00 – 17:00  
Location: C1-M3 (Ground floor)

784

New DBS targets for dystonia in thalamus and brainstem

1184

Encoding of action plans and confidence in the human basal ganglia-thalamic circuit

## Session 3412

Tuesday, August 30, 2023  
Location: Auditorium 10-11 (First floor)

1193

In vitro  $\alpha$ -synuclein aggregation and propagation model

## Session 4413

Wednesday, August 31, 15:00 – 17:00  
Location: C1-M1 (Ground floor)

427

Assessing non-motor symptoms and associations with quality of life among patients in Korle-Bu Teaching Hospital, Ghana

561

Expanding the reach of a telehealth psychotherapy hub to advance coordinated depression care for rural veterans with Parkinson's Disease

**Session 4414**

Wednesday, August 31, 15:00 – 17:00

Location: C1-M2 (Ground floor)

953

Automatic assessment of tic expression using selfie-video

954

Premonitory urge in patients with tics and functional tic-like behaviors

**Session 4415**

Wednesday, August 31, 15:00 - 17:00

Location: C1-M3 (Ground floor)

131

Preliminary Report on Neuromelanin-Sensitive MRI Signal change after Allogeneic Bone marrow-derived Mesenchymal Stem Cells therapy: Phase IIa double-blind, randomized controlled trial

270

Transcriptional dysregulation in iPSC-derived neurons from patients with X-linked dystonia-parkinsonism

**Session 4416**

Wednesday, August 31, 15:00 – 17:00

Location: C1-M4/C1-M5 (Ground floor)

33

A staged screening paradigm to identify people at risk of Parkinson's disease in the Parkinson's Progression Markers Initiative

94

Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson's disease (PD): the LIXIPARK trial (NCT03439943)

**Session 4417**

Wednesday, August 31, 15:00 – 17:00

Location: Auditorium 15 (First floor)

211

18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy

1571

Clinical severity in Parkinson's disease is determined by decline in cortical compensation

**Session 4418**

Wednesday, August 31, 15:00 – 17:00

Location: Auditorium 10-11 (First floor)

1436

Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson's disease

1437

Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson's Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment